Company Overview

Genfit S.A. is a France‑based late‑stage biopharmaceutical company focused on the discovery and development of therapies for rare and chronic liver diseases with significant unmet medical needs. The company operates within the biotechnology and pharmaceutical research and development industries, with a core emphasis on metabolic and cholestatic liver disorders. Its primary value creation is driven by proprietary drug candidates and related intellectual property rather than commercial-scale manufacturing.

Genfit was founded in 1999 and has evolved from an early‑stage metabolic disease research company into a clinical‑stage biopharmaceutical developer with one approved therapy. The company’s strategic positioning is centered on deep scientific expertise in liver pathophysiology, nuclear receptor biology, and translational medicine. Genfit is best known for developing elafibranor, which represents its most significant clinical and commercial asset to date.

Business Operations

Genfit’s operations are organized around research, clinical development, regulatory approval, and lifecycle management of liver disease therapies. The company historically focused on metabolic dysfunction–associated steatohepatitis (MASH/NASH) but has since narrowed its strategic emphasis to primary biliary cholangitis (PBC) and other rare cholestatic liver diseases following clinical trial outcomes. Revenue generation is primarily driven by milestone payments, licensing agreements, and collaboration income, rather than direct product sales.

The company conducts R&D activities through its French headquarters and its U.S. subsidiary Genfit Corp., which supports regulatory and clinical operations in North America. Genfit maintains strategic partnerships, most notably with Ipsen, which holds commercialization rights for elafibranor in certain territories. Genfit retains responsibility for ongoing development activities and select geographic rights, depending on the indication and region.

Strategic Position & Investments

Genfit’s strategic direction focuses on maximizing the value of elafibranor following its regulatory approval for PBC and expanding its liver disease pipeline through targeted internal research and external collaborations. A major strategic milestone was the regulatory approval of elafibranor (marketed as Iqirvo) for PBC, which repositioned the company from a development‑only entity to a revenue‑participating biopharmaceutical firm.

Beyond elafibranor, Genfit invests in early‑stage assets targeting rare liver diseases and diagnostic technologies related to metabolic and fibrotic liver conditions. The company has pursued portfolio optimization by discontinuing non‑viable programs and reallocating capital toward assets with clearer regulatory and commercial pathways. No material diversified equity investment portfolio has been disclosed beyond its operating subsidiaries and partnered programs.

Geographic Footprint

Genfit is headquartered in France, with its principal offices located in the Lille region. The company maintains an operational presence in North America through Genfit Corp. in the United States, which plays a key role in regulatory interactions with U.S. authorities and clinical development activities.

Commercial and strategic reach extends across Europe, North America, and select international markets through licensing arrangements, particularly with Ipsen, which supports commercialization outside certain retained territories. While Genfit does not operate large-scale global infrastructure, its clinical trials, regulatory filings, and partnerships give it an international operational footprint disproportionate to its physical size.

Leadership & Governance

Genfit was founded by Jean‑François Mouney, who continues to play a central role in the company’s governance and long‑term strategic vision. The leadership team emphasizes scientific rigor, capital discipline, and focused execution in rare disease drug development, particularly following lessons learned from prior late‑stage clinical setbacks.

Key executives include:

• Pascal Prigent – Chief Executive Officer
• Jean‑François Mouney – Co‑Founder and Chairman of the Board
• Frédéric Bastian – Chief Financial Officer
• Barbara Belleville – Chief Medical Officer
• Stéphane Huet – Chief Scientific Officer

The board and executive leadership maintain a governance framework aligned with European public company standards, with oversight focused on risk management, regulatory compliance, and long‑term value creation through innovation in liver disease therapeutics.